hVIVO (LON:HVO) Shares Pass Below 50 Day Moving Average - Here's Why

Key Points

• hVIVO plc's stock price fell below its 50-day moving average for the first time, currently trading at GBX 9.12 ($0.12), indicating a potential sell signal.
• Analysts have set new price targets for hVIVO, with Shore Capital maintaining a "buy" rating" and a target of GBX 35, while the consensus target price stands at GBX 28.
• The company's market cap is £67.33 million, with a price-to-earnings ratio of 632.06, reflecting high valuation expectations amidst its involvement in human challenge clinical trials.

hVIVO plc (LON:HVO - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 10.15 ($0.14) and traded as low as GBX 9.12 ($0.12). hVIVO shares last traded at GBX 9.12 ($0.12), with a volume of 837,810 shares.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HVO. Peel Hunt reiterated an "add" rating and set a GBX 21 price target on shares of hVIVO in a report on Tuesday, July 29th. Shore Capital reaffirmed a "buy" rating and set a GBX 35 price target on shares of hVIVO in a research report on Tuesday, July 22nd. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of GBX 28.

hVIVO Stock Up 1.4%

The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The company has a market cap of £64.67 million, a P/E ratio of 607.10 and a beta of 0.97. The stock's 50-day moving average price is GBX 10.07 and its 200-day moving average price is GBX 13.08.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.